4.3 Article

Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors

期刊

JOURNAL OF CARDIOLOGY
卷 66, 期 1-2, 页码 22-27

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jjcc.2014.11.006

关键词

Atherosclerosis; Cardiovascular risk factors; Biomarkers; Fibroblast growth factor-23; Monocyte chemoattractant protein-1

资金

  1. Fondo de Investigaciones Sanitarias [PI05/0451, PI05/1497, PI05/52475, PI05/1043, PS09/01405, PI10/00072, PI14/01567]
  2. Spanish Society of Cardiology
  3. Spanish Heart Foundation
  4. Spanish Society of Arteriosclerosis
  5. RECAVA [RD06/0014/0035]
  6. Fundacion Lilly
  7. Instituto de Salud Carlos III FEDER [FJD Biobank: RD09/0076/00101]
  8. AbbVie Laboratories

向作者/读者索取更多资源

Background: Patients with coronary heart disease (CHD) without classical cardiovascular risk factors (CRFs) are uncommon, and their profile has not been thoroughly studied. In CHD patients, we have assessed the differences in several biomarkers between those with and without CRF. Methods: We studied 704 patients with CHD, analyzing plasma levels of biomarkers related to inflammation, thrombosis, renal damage, and heart failure: high-sensitivity C-reactive protein (hs-CRP), monocyte chemoattractant protein-1 (MCP-1), galectin-3, N-terminal fragment of brain natriuretic peptide (NT-pro-BNP), calcidiol (vitamin D metabolite), fibroblast growth factor-23 (FGF-23), parathormone, and phosphate. Results: Twenty patients (2.8%) exhibited no CRFs. Clinical variables were well balanced in both groups, with the logical exceptions of no use of antidiabetic drugs, lower triglyceride and glucose, and higher high-density lipoprotein cholesterol in no-CRF patients. No-CRF patients showed lower hs-CRP (2.574 +/- 3.120 vs. 4.554 +/- 9.786 mg/L; p = 0.018), MCP-1 (114.75 +/- 36.29 vs. 143.56 +/- 65.37 pg/ml: p = 0.003), and FGF-23 (79.28 +/- 40.22 vs. 105.17 +/- 156.61 RU/ml; p = 0.024), and higher calcidiol (23.66 +/- 9.12 vs. 19.49 +/- 8.18 ng/ml; p = 0.025) levels. At follow-up, 10.0% vs. 11.0% patients experienced acute ischemic event, heart failure, or death in the non-CRF and CRF groups, respectively (p = 0.815, log-rank test). The limited number of non-CRF patients may have influenced this finding. A Cox regression analysis in the whole population showed that high calcidiol, and low MCP-1 and FGF-23 plasma levels are associated with a better prognosis. Conclusions: CHD patients without CRFs show a favorable biomarker profile in terms of inflammation and mineral metabolism. Further studies are needed to investigate whether this difference translates into a better prognosis. (C) 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据